Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab.
Ligation of the jugular veins does not result in brain inflammation or demyelination in mice.
Pediatric multiple sclerosis in Venezuela.
Building a better sphingosine kinase-1 inhibitor.
Reward responsiveness and fatigue in multiple sclerosis.
Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates.
Transcriptional enhancers: from properties to genome-wide predictions.
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 mg GA Depot in Subjects With RRMS
The effect of vitamin a supplementation on disease progression, cytokine levels and gene expression in multiple sclerotic patients: study protocol for a randomized controlled trial.
RNF and Betaseron® Tolerability Study (REFORMS)
Behçet's Disease Presenting with Acute Transverse Myelitis: MRI Findings and Review of the Nosology. A Case Report.
Deep 3D Convolutional Encoder Networks with Shortcuts for Multiscale Feature Integration Applied to Multiple Sclerosis Lesion Segmentation.
Recurrence of disease activity after repeated Natalizumab withdrawals.
[Inflammatory brain pseudotumor. A variant of demyelinating disease that simulates high-grade glioma].
A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C.
Genzyme’s Lemtrada® approved in Mexico for treatment of multiple sclerosis
Study shows promising efficacy for peginterferon beta-1a in multiple sclerosis
▼Dimethyl fumarate for relapsing-remitting multiple sclerosis.
N-Acetylcysteine amide: A Derivative to Fulfill the Promises of N-Acetylcysteine.
Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study.
Bayer Receives FDA Approval for BETACONNECT - First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment
Guillain-Barré syndrome in Colombia: where do we stand now?
COMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
Cognitive and Behavioral Outcomes in Individuals With a History of Acute Disseminated Encephalomyelitis (ADEM).
Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis.

Pages